$ALC News

Alcon: Keeping An Eye Out Here Amid Sales And Margin Momentum

Alcon's Neurotech Acquisition Offers Significant Growth Potential, Needham Says

Needham Reiterates Buy on Alcon, Maintains $98 Price Target

Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

Alcon Acquires Neurotech Pharmaceuticals For $550M

FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.

BTIG Maintains Buy on Alcon, Lowers Price Target to $74

Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70

Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief

Alcon (SWX:ALC) Stock Trades Above Fair Value On Earnings Pressure

Needham Reiterates Buy on Alcon, Maintains $98 Price Target

Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control

Are Options Traders Betting on a Big Move in Alcon Stock?

Alcon: A Re-Rating In Eyesight

Alcon Prices EUR 500 Million Senior Notes Offering

SGA Exits Alcon (ALC) as Cataract Demand Slows and Competition Rises

What Makes Alcon (ALC) a Bullish Bet?

Alcon (ALC) Q2 2026 Earnings Call Transcript

Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy